Can you tell me the criteria? For the different three phases seen in chronic myeloid leukemia. In Harrison's 21nd edition, I read something else while... In Marrow MCQ question banks I read something else entirely. So I'd like for you to tell me what is the most updated recent criteria given in the... 22nd edition of Harrison.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
I now have the complete, verbatim criteria from Harrison's 22E. Let me compile the full answer.
Here is everything from Harrison's Principles of Internal Medicine, 22nd Edition (2025) on the three phases of CML, taken directly from Chapter 110 (page 881):
CML Phase Criteria - Harrison's 22nd Edition (2025)
Phase 1: Chronic Phase
This is the indolent, initial phase. About 90% of patients present in chronic phase. Key findings include:
- Peripheral blood: leukocytosis (10-500 x 10⁹/L), left-shifted differential with neutrophils, bands, myelocytes, metamyelocytes, promyelocytes, and blasts (usually ≤5%)
- Basophilia and/or eosinophilia frequently present
- Bone marrow blasts: typically ≤5% (when ≥15%, it signals worse prognosis or transformation to accelerated phase)
- Low leukocyte alkaline phosphatase score
- BCR::ABL1 fusion gene present (Ph chromosome)
The chronic phase is NOT strictly defined by a blast cutoff list of criteria the way the other phases are - it is essentially the default phase before the accelerated/blastic criteria are met.
Phase 2: Accelerated Phase
Harrison's 22E gives classic (historical) criteria for accelerated phase - defined as criteria historically associated with a median survival of <2 years:
| Criterion | Threshold |
|---|---|
| Peripheral blood blasts | ≥15% |
| Peripheral blood blasts + promyelocytes | ≥30% |
| Peripheral blood basophils | ≥20% |
| Cytogenetic clonal evolution | Additional chromosomal abnormalities beyond Ph chromosome |
| Thrombocytopenia | <100 x 10⁹/L (unrelated to therapy) |
Important caveat in the 22nd edition: Harrison's explicitly notes that "the criteria for accelerated-phase CML should be revisited because most clinical criteria defining accelerated phase have lost much of their prognostic significance" in the TKI era. The prognosis of de novo accelerated phase has improved significantly - 8-year survival is now 60-70% with TKI therapy.
On WHO classification: The newest WHO classification (WHO 5th edition, 2022) actually suggested eliminating accelerated-phase CML as a separate entity and reclassifying such patients simply as "high-risk CML." However, Harrison's 22E explicitly states: "The accelerated-phase definition should be maintained in order to recognize such patients and treat them differently than chronic-phase CML."
This is the key discrepancy you were seeing - WHO 5th edition (referenced in Marrow and newer MCQ banks) removes the accelerated phase as a distinct category, while Harrison's 22E argues the designation should be kept for practical clinical management.
Phase 3: Blastic Phase (Blast Crisis)
Blastic-phase CML is defined by either of the following (Harrison's 22E, p. 881):
| Criterion | Threshold |
|---|---|
| Peripheral blood OR bone marrow blasts | ≥30% |
| Sheets of blasts in extramedullary disease | (skin, soft tissues, or lytic bone lesions) |
Subtypes of blastic phase:
- Myeloid blastic phase: ~60% of cases (most common)
- Lymphoid blastic phase: ~25% of cases
- TdT positive, peroxidase negative
- Expresses CD10, CD19, CD20, CD22
- Responsive to hyper-CVAD + TKIs (complete response ~70%)
- Less common: erythroid, promyelocytic, monocytic, megakaryocytic
Key Summary: What Harrison's 22E Says vs. What You Read Elsewhere
| Criterion | Harrison's 22E (2025) | WHO 5th Ed / ICC 2022 (Marrow MCQ) |
|---|---|---|
| Accelerated phase blasts | ≥15% peripheral | Eliminated as category; ≥10-19% = "high-risk" |
| Blasts + promyelocytes | ≥30% | Not used in same way |
| Basophils | ≥20% | - |
| Blastic phase cutoff | ≥30% blasts | ≥20% blasts (WHO 5th edition lowered this) |
| Accelerated phase status | Maintained | Eliminated (called "high-risk CML") |
The biggest practical difference: WHO 5th edition (2022) lowered the blastic phase blast threshold from ≥30% to ≥20%, and removed accelerated phase as a separate entity. Harrison's 22E acknowledges this but argues the older thresholds and the accelerated phase category should still be used clinically.
So when you see "≥20% blasts = blast phase" in newer MCQ banks - that reflects WHO 2022. When Harrison's says "≥30% blasts = blast phase" - that is the classic criterion that Harrison's 22E continues to use and endorse.
- Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 110, p. 881
In Marrow, I read that accelerated phase is characterized by any one of... Well, number one, blasts comprising 10 to 19% of WBCs in peripheral blood and/or bone marrow. Number two, peripheral blood basophils more than equal to 20%. Number three, thrombocytopenia or thrombocytosis not responsive to therapy. And number four, additional cytogenetic abnormalities in Philadelphia chromosome cells.
Finding Sources
Finding Sources
Reading File
Now I have the complete, authoritative comparison from multiple sources. Here is the full breakdown:
What You Read in Marrow - Where It Comes From
The criteria you listed from Marrow are the ICC (International Consensus Classification) 2022 criteria for accelerated phase. Here is the precise breakdown of all three classification systems side by side:
Three Classification Systems - Head to Head
Accelerated Phase Criteria
| Criterion | WHO 4th Ed (old) | ICC 2022 (Marrow) | WHO 5th Ed 2022 | Harrison's 22E |
|---|---|---|---|---|
| Blasts | 15-29% PB/BM | 10-19% PB and/or BM | Phase eliminated | ≥15% peripheral blasts |
| Blasts + promyelocytes | ≥30% | Not used | - | ≥30% |
| Basophils | ≥20% | ≥20% | - | ≥20% |
| Thrombocytopenia | <100 x 10⁹/L unrelated to therapy | Thrombocytopenia OR thrombocytosis, not responsive to therapy | - | <100 x 10⁹/L uncorrected to therapy |
| Cytogenetic clonal evolution | Any ACA | Only "major route" ACAs (see below) | - | Any ACA beyond Ph |
| Splenomegaly resistant to therapy | Yes (included) | Not included | - | Not listed |
The Key Difference on "Clonal Evolution" - ICC Refined This
The ICC 2022 narrowed the cytogenetic criterion from any additional chromosomal abnormality to only "major route" ACAs:
- Second (duplicate) Philadelphia chromosome
- Trisomy 8
- Isochromosome 17q
- Trisomy 19
- Complex karyotype
- Abnormalities of 3q26.2
Minor route ACAs (like -Y, +der(22)) no longer qualify as accelerated phase under ICC 2022.
Blastic Phase Criteria
| Criterion | WHO 4th Ed | ICC 2022 | WHO 5th Ed 2022 | Harrison's 22E |
|---|---|---|---|---|
| Blast threshold | ≥20% PB or BM | ≥20% PB or BM | ≥20% PB or BM | ≥30% PB or BM |
| Extramedullary disease | Myeloid sarcoma | Myeloid sarcoma | Myeloid sarcoma | Sheets of blasts in skin/soft tissue/bone |
| Lymphoblastic crisis | Included | ≥5% morphological lymphoblasts (immunophenotyping required) | Bona fide lymphoblasts even if <10% | ~25% of blastic phase cases |
The Structural Difference: How Many Phases?
This is the biggest conceptual divide:
- WHO 5th Edition (2022): Only 2 phases - Chronic Phase and Blast Phase. Accelerated phase is eliminated; those patients are reclassified as "high-risk CML."
- ICC 2022 (what Marrow follows): Retains 3 phases - Chronic, Accelerated, and Blast.
- Harrison's 22E: Uses the traditional 3 phases, cites the classic criteria (≥15% blasts, ≥30% blasts+promyelocytes), acknowledges the WHO 5th edition change, but argues the accelerated phase designation should be maintained for clinical decision-making.
Why the Blast Threshold Differs (30% vs 20%)
Harrison's 22E still lists ≥30% for blast phase because it follows the older classification that was in use for decades. All three modern classifications (WHO 4th, WHO 5th, and ICC 2022) use ≥20% as the blast phase cutoff. Harrison's 22E is internally inconsistent here - it acknowledges the newer WHO 5th edition but does not update its own stated criteria to match. The ≥20% threshold is considered more current and is what Marrow, newer pathology resources, and the ICC/WHO 2022 documents use.
Bottom Line for Exams
| Question | Answer |
|---|---|
| Marrow / ICC 2022 blasts for accelerated phase | 10-19% |
| Harrison's 22E blasts for accelerated phase | ≥15% |
| Blast phase cutoff (all modern systems) | ≥20% |
| Harrison's 22E blast phase cutoff | ≥30% (older criterion) |
| WHO 5th Ed - accelerated phase | Does not exist - eliminated |
| ICC 2022 - accelerated phase | Retained (3 phases) |
For Indian PG exams (NEET PG, INI-CET), Marrow typically follows ICC 2022 criteria, which use 10-19% blasts for accelerated phase and ≥20% for blast crisis. This is the more widely accepted current standard globally, even though Harrison's 22E uses slightly different numbers internally.
Sources: Harrison's 22E Ch. 110 p. 881; Quick Compendium of Clinical Pathology 5th Ed., Section 4.3.7.6.3.1
Isn't Harrison supposed to be the gold standard? And the newest edition being 22nd edition, shouldn't it be updated?
Finding Sources
Searching PubMed
"chronic myeloid leukemia" AND "accelerated phase" AND classification
Reading Article
PMID: 39638957
Finding Sources
Good. I now have everything I need to give a thorough, honest answer to this question. Here it is:
Is Harrison's the Gold Standard? Should the 22nd Edition Be Updated?
Both fair questions. The honest answers are: yes, Harrison's is a gold standard - but not in the way most people think, and yes, Harrison's 22E is genuinely inconsistent on this topic.
What "Gold Standard" Actually Means for Harrison's
Harrison's is the gold standard for pathophysiology, clinical reasoning, and internal medicine management. It is written by clinical experts - hematologists, oncologists, physicians who treat patients. It is not a classification authority. Classification systems are formally issued by:
- WHO (World Health Organization) - via the Classification of Tumours series (Haematopoietic and Lymphoid Tumours)
- ICC (International Consensus Classification) - published in Blood (2022) by an international expert panel
These bodies set the official diagnostic criteria. Harrison's follows them, cites them, and comments on them - but it does not define them. When there is a conflict between Harrison's and WHO/ICC on classification criteria, the WHO/ICC documents are the authoritative source.
Where Harrison's 22E Falls Short on This Topic
Here is the honest assessment - Harrison's 22E is internally aware of the newer classifications but does not fully adopt them. The text itself says:
"The criteria for accelerated-phase CML should be revisited because most clinical criteria defining accelerated phase have lost much of their prognostic significance."
It acknowledges the WHO 5th edition change, argues against it on clinical grounds, and then continues listing the old criteria (≥15% blasts, ≥30% blasts + promyelocytes). That is a deliberate editorial position by the chapter author (Dr. Hagop Kantarjian, MD Anderson), not an oversight. He is essentially saying: "I know what WHO said, I disagree with eliminating accelerated phase, and here is why."
That is a legitimate expert opinion - but it means the criteria in Harrison's 22E reflect the author's clinical position, not the current official classification.
A 2025 review published in Drugs (Atallah & Deininger, PMID 39638957) specifically noted:
"The definition of these categories has been in continuous flux over the last 20 years, making applicability of data even more confusing. In some classifications, the cutoff is 30% blasts for the definition of BP-CML, while in others a cutoff of 20% is used."
So even leading CML experts in 2025 acknowledge this is an active, unresolved debate - not a settled matter where one source is simply "right."
How to Think About This for Different Purposes
| Purpose | Follow Which Source |
|---|---|
| NEET PG / INI-CET exams | ICC 2022 criteria (what Marrow uses) - 10-19% blasts = AP, ≥20% = BP |
| USMLE / international exams | WHO 5th Ed - only 2 phases; ≥20% = blast phase |
| Clinical practice in India | ICC 2022 (most haematology departments use this) |
| Understanding pathophysiology | Harrison's 22E is excellent |
| Classification authority | WHO / ICC publications, not Harrison's |
The Short Answer to Your Question
Harrison's 22E is not outdated - it is deliberately non-conforming on this point. The chapter author chose to retain older criteria and argue against the WHO 5th edition change. That is his expert prerogative, and his argument has clinical merit (accelerated phase patients do behave differently and should be treated differently). But for examination purposes, the ICC 2022 criteria that Marrow uses (10-19% blasts for AP, ≥20% for blast phase) are the more widely accepted current standard, and they are what classification examiners test on.
Harrison's is the gold standard for understanding disease - but for classification criteria, WHO and ICC are the gold standard. They are two different kinds of authority.
This is a shared conversation. Sign in to Orris to start your own chat.